Business Wire

CA-BELKIN

Share
Belkin celebrates 40 years of industry leadership by introducing a more responsible way to build products

Belkin, a global consumer electronics leader, after two years of development, today introduces a new product material refresh for its top selling mobile power products. Several of Belkin’s most popular wireless chargers, power banks, wall chargers, and car chargers will receive updated product housing materials that consist of 73-75% post-consumer recycled plastics (PCR) and plastic-free packaging. The product transition will be rolled out beginning 2023 and will save an estimated 7,000 metric tons of carbon emissions1 and reduce CO2-eq emissions for these products by up to 67%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005370/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

The company celebrates 40 years as a market leader and innovator by honoring its deeply rooted commitment to sustainability. Belkin is already on its way to becoming 100% carbon neutral in scope 1 & 2 emissions by 2025. Its commitment to reviewing all areas of the business has included a focus on reducing single-use plastics in packaging which has seen up to a 90% reduction in plastic usage in some products. Today’s announcement addresses Belkin’s approach to reducing its scope 3 emissions.

Belkin made a deliberate and methodical decision to transition product materials to PCR. This takes plastic waste from consumers and repurposes it to create new products. It utilizes plastic that is destined for landfill, giving it new life, while taking meaningful steps to support the circular economy by reducing dependence on virgin plastics. The Life Cycle Assessment conducted by the company shows that utilizing PCR material has a significant reduction in environmental impact.

There are other plastic alternatives in the industry such as:

  • Recycled plastic (PIR), a method that reuses plastic materials collected at a factory during mass production
  • Bioplastics, which uses materials from renewable feedstocks such as plants and woodchips
  • Ocean plastics, which reuses plastic waste collected from the ocean

“When we think about the difference a company of our size and influence can make on the planet, moving away from using virgin plastics in our products is an obvious decision,” said Steve Malony, CEO, Belkin. “I am proud to work alongside the teams that made this shared vision a reality. Their dedication to doing the right thing inspires me and together, we will continue to work towards a more sustainable future.”

The following products will be the first to ship with the new PCR material throughout 2023:

From an aesthetic, quality and engineering perspective, there will be little difference between existing Belkin products and Belkin PCR products. Consumers will be able to decipher the new PCR products by clear callouts on the packaging and product pages online such as: “Made with Recycled Plastic Products” and “100% Plastic Free Packaging.”

Belkin’s engineering and product development teams are based in Los Angeles, Hong Kong, Shenzhen, Vietnam and Taiwan, and work tirelessly to develop innovation that changes the way people connect with their technology while reducing impact on the planet. Belkin takes quality seriously, and nothing enters the market until rigorous testing and approval processes take place. For this new PCR portfolio, Belkin additionally continues to explore new solutions and to conscientiously verify the science behind how Belkin can further reduce its impact on the planet while not compromising on quality. PCR material was sourced from reputable resin vendors and selected and tested by Belkin’s design assurance team.

To learn more about Belkin Sustainability, visit: https://www.belkin.com/company/sustainability/

Press kit can be found here.

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remain forever inspired by people and the planet we live on.

1 Based on forecasted calculations from May 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005370/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye